Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone

Journal of Orthopaedic Research

Volumn 29, Issue 3, 2011, Pages 403-413

  Lau, Carol P Y ^a   Huang, Lin ^b   Tsui, Stephen K W ^b   Ng, Patrick K S ^b   Leung, Pui Yin ^b   Kumta, Shekhar M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

apoptosis; bisphosphonates; giant cell tumor of bone; protein prenylation inhibitors; RANKL

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; GGTI 298; MESSENGER RNA; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PROTEIN FARNESYLTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OSTEOCLASTOMA; PRIORITY JOURNAL; STROMA CELL;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BENZAMIDES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CASPASES; CELL DIVISION; CELL SURVIVAL; DIPHOSPHONATES; DRUG SYNERGISM; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENE EXPRESSION; GIANT CELL TUMOR OF BONE; HUMANS; METHIONINE; OSTEOPROTEGERIN; PRENYLATION; RANK LIGAND; RNA, MESSENGER; S PHASE; TUMOR CELLS, CULTURED;

EID: 79251567386     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21249     Document Type: Article

References (43)

1. Yip MH, Leung PC, Kumta SM,. 1996. Giant cell tumor of bone. Clin Orthop 323: 60-64.
2. Ghert MA, Rizzo M, Harrelson JM, et al. 2002. Giant cell tumor of the appendicular skeleton. Clin Orthop 400: 201-210.
3. Rock MG,. 1990. Curettage of giant cell tumor of bone: Factors influencing local recurrences and metastasis. Chir Organi Mov 75: 43-46.
4. Goldring SR, Schiller AL, Mankin HJ, et al. 1986. Characterization of cells from human giant cell tumors of bone. Clin Orthop 204: 59-75.
5. Zheng MH, Robbins P, Xu J, et al. 2001. The histogenesis of giant cell tumor of bone: A model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 16: 297-307.
6. Liao TS, Yurgelun MB, Chang SS, et al. 2005. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 23: 203-209.
7. Robinson D, Einhorn TA,. 1994. Giant cell tumor of bone: A unique paradigm of stroma-hematopoietic cellular interactions. J Cell Biochem 55: 300-303.
8. Cheng YY, Huang L, Kumta SM, et al. 2003. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 27: 385-391.
9. Cheng YY, Huang L, Lee KM, et al. 2004. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 75: 71-77.
10. Van beek E, Lowik C, van der Pluijm G, et al. 1999. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14: 722-729.
11. Appels NM, Beijnen JH, Schellens JH,. 2005. Development of farnesyl transferase inhibitors: A review. Oncologist 10: 565-578.
12. Peterson YK, Kelly P, Weinbaum CA, et al. 2006. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 281: 12445-12450.
13. Konstantinopoulos PA, Papavassiliou AG,. 2007. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci 28: 6-13.
14. Huang L, Xu J, Wood DJ, et al. 2000. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156: 761-767.
15. Joyner CJ, Quinn JM, Triffitt JT, et al. 1992. Phenotypic characterization of mononuclear and multinucleated cells of giant cell tumor of bone. Bone Miner 16: 37-48.
16. Robinson D, Lewis MM, Nevo Z, et al. 1997. The radiographic stage of giant cell tumor related to stromal cells proliferation: Tissue cultures in 13 cases. Acta Orthop Scand 68: 294-297.
17. Huang L, Teng XY, Cheng YY, et al. 2004. Expression of preosteoblast markers and Cbfa-1 and osterix gene transcripts in stromal tumour cells of giant cell tumor of bone. Bone 34: 393-401.
18. Rodan SB, Imai Y, Thiede MA, et al. 1987. Characterization of a human osteosarcoma cell line (SaOS2) with osteoblastic properties. Cancer Res 47: 4961-4966.
19. Cheng YY, Huang L, Lee KM, et al. 2004. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 42: 410-415.
20. Chou TC, Talalay P,. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
21. Manocha S, Matrai Z, Osthoff M, et al. 2003. Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia. Leuk Lymphoma 44: 797-800.
22. Iguchi T, Miyakawa Y, Yamamoto K, et al. 2003. Nitrogen containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15: 719-727.
23. Lee MV, Fong EM, Singer FR, et al. 2001. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608.
24. Murayama T, Kawasoe Y, Yamashita Y, et al. 2008. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anti-cancer drugs against osteosarcoma cell lines. Anticancer Res 28: 2147-2154.
25. Kubista B, Trieb K, Sevelda F, et al. 2006. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24: 1145-1152.
26. Dunford JE, Rogers MJ, Ebetino FH, et al. 2006. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21: 684-693.
27. Coleman ML, Marshall CJ, Olson MF,. 2003. Ras promotes p21Waf1/Cip1 protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 22: 2036-2046.
28. Fromigue O, Body JJ,. 2002. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25: 539-546.
29. Im GI, Qureshi SA, Kenney J, et al. 2004. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25: 4105-4115.
30. Reinholz GG, Getz B, Pederson L, et al. 2000. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60: 6001-6007.
31. Plotkin LI, Weinstein RS, Parfitt AM, et al. 1999. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374.
32. Heino TJ, Chagin AS, Takigawa M, et al. 2008. Effects of alendronate and pamidronate on cultured rat metatarsal bones: Failure to prevent dexamethasone-induced growth retardation. Bone 42: 702-709.
33. Idris A, Rojas J, Greig IR, et al. 2008. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82: 191-201.
34. Kellinsalmi M, Mönkkönen H, Mönkkönen J, et al. 2005. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97: 382-391.
35. García-Moreno C, Serrano S, Nacher M, et al. 1998. Effect of alendronate on cultured normal human osteoblasts. Bone 22: 233-239.
36. Naidu A, Dechow PC, Spears R, et al. 2008. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106: 5-13.
37. Pan B, To LB, Farrugia AN, et al. 2004. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralization of human bone-derived cells in vitro. Bone 34: 112-123.
38. Yoshida T, Clark MF, Stern PH,. 2009. The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival. J Cell Biochem 106: 896-902.
39. Mazet JL, Padieu M, Osman H, et al. 1999. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. FEBS Lett 460: 235-240.
40. Morgan MA, Wegner J, Aydilek E, et al. 2003. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia 17: 1508-1520.
41. Morgan MA, Sebil T, Aydilek E, et al. 2005. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signaling in multiple myeloma cells. Br J Haematol 130: 912-925.
42. Pan B, Farrugia AN, To LB, et al. 2004. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19: 147-154.
43. Mackie PS, Fishier JL, Zhou H, et al. 2001. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84: 951-958.